Involvement of lymphatics in lymphangioleiomyomatosis.
Lymphangioleiomyomatosis (LAM), a rare multisystem disease, occurs primarily in women, with cystic destruction of the lungs, abdominal tumors, and involvement of the axial lymphatics in the thorax and abdomen. To understand the pathogenesis of LAM, we initiated a longitudinal study of patients with LAM; over 500 patients have been enrolled. LAM results from the proliferation of a neoplastic cell (LAM cell), which has mutations in the tuberous sclerosis complex (TSC) genes, TSC1 or TSC2. Consistent with their metastatic behavior, LAM cells were isolated from blood, urine, and chylous effusions. Surface proteins on LAM cells include those found on metastatic cells and those involved in cell migration. In the lung, LAM cells are found clustered in nodules, which appear in the walls of the cysts, and in the interstitium. LAM lung nodules are traversed by slit-like vascular structures, with lining cells showing reactivity with antibodies against components of lymphatic endothelial cells. The axial lymphatics appear to be infiltrated by LAM cells, which may result in obstruction and formation of chyle-filled lymphangioleiomyomas. LAM cell clusters have been isolated from chylous pleural effusions, and it is hypothesized that these clusters may be responsible for metastatic spread of LAM cells via lymphatic vessels. Consistent with a lymphangiogenic process, levels of VEGF-D, a lymphangiogenic factor, were higher in sera of patients with LAM and lymphatic involvement (i.e., lymphangioleiomyoma, adenopathy) than in healthy volunteers or LAM patients with cystic disease limited to the lung. These findings are consistent with an important function for lymphangiogenesis in LAM.
Translational Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892-1590, USA.
Connie G
CG
Glasgow
Angelo
A
Taveira-DaSilva
Gustavo
G
Pacheco-Rodriguez
Wendy K
WK
Steagall
Katsuya
K
Tsukada
Xiong
X
Cai
Souheil
S
El-Chemaly
Joel
J
Moss
D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D042583:Lymphangiogenesis / Q000502:physiology; D018192:Lymphangioleiomyomatosis / Q000097:blood / Q000209:etiology* / Q000473:pathology; D042601:Lymphatic Vessels / Q000502:physiology*; D008297:Male; D012189:Retrospective Studies; D042643:Vascular Endothelial Growth Factor D / Q000097:blood
D042643:Vascular Endothelial Growth Factor D